Adverse events: hypertension · patients with Guillain‐Barré syndrome
Corticosteroid leads to lower adverse events ‐ hypertension compared with control (high certainty).
1 finding from 1 review
Incomplete recovery at end of study House‐Brackmann scale, Sunnybrook score, Yanagihara score · Bell's palsy
Corticosteroids leads to lower incomplete recovery ≥ 6 months after randomisation House‐Brackmann… compared with placebo or no treatment (high certainty).
1 finding from 1 review
Cosmetically disabling persistent sequelae ≥ 6 months after randomisation Clinical assessment · Bell's palsy
Corticosteroids showed no clear difference in cosmetically disabling persistent sequelae ≥ 6 months after… compared with placebo or no treatment (low certainty).
1 finding from 1 review
Motor synkinesis or crocodile tears Clinical assessment · Bell's palsy
Corticosteroids probably leads to lower motor synkinesis and crocodile tears Clinical assessment compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
Adverse effects · Bell's palsy
Corticosteroids showed no clear difference in adverse effects compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
Number of participants improved in disability · patients with IgM anti‐myelin‐associated glycoprotein paraprotein‐associated peripheral neuropathies
Rituximab may leads to higher number of participants improved in disability compared with placebo (low certainty).
1 finding from 1 review
Mean improvement in disability · patients with IgM anti‐myelin‐associated glycoprotein paraprotein‐associated peripheral neuropathies
1 finding from 1 review
Improvement in 10‐metre walk time at 8 to 12 months1 · patients with IgM anti‐myelin‐associated glycoprotein paraprotein‐associated peripheral neuropathies
1 finding from 1 review
Participant subjective impression of change stable or improved at 8 to 12 months · patients with IgM anti‐myelin‐associated glycoprotein paraprotein‐associated peripheral neuropathies
Rituximab may leads to higher participant subjective impression of change stable or improved at 8… compared with placebo (low certainty).
1 finding from 1 review
Change in serum IgM paraprotein concentration 8 months after treatment1 · patients with IgM anti‐myelin‐associated glycoprotein paraprotein‐associated peripheral neuropathies
1 finding from 1 review
Any adverse event · patients with IgM anti‐myelin‐associated glycoprotein paraprotein‐associated peripheral neuropathies
It is very uncertain whether rituximab changes any adverse event compared with placebo (very low certainty).
1 finding from 1 review
Prolongation of time to loss of ambulation ‐ not reported · patients with Duchenne muscular dystrophy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in muscle strength ‐ QMT leg score (lb) · patients with Duchenne muscular dystrophy
1 finding from 1 review
Muscle strength · patients with Duchenne muscular dystrophy
2 findings from 1 review
Change in 10‐metre walking time · patients with Duchenne muscular dystrophy
1 finding from 1 review
Change in 4‐stair climbing time · patients with Duchenne muscular dystrophy
1 finding from 1 review
Body‐mass index (BMI) · patients with Duchenne muscular dystrophy
1 finding from 1 review
Behavioural changes · patients with Duchenne muscular dystrophy
1 finding from 1 review
Fractures ‐ not reported · patients with Duchenne muscular dystrophy
1 finding from 1 review
Prolongation of time to loss of ambulation ‐ not reported · patients with Duchenne muscular dystrophy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found